The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis
This observational study aims to investigate how smoking and periodontal health affect lipid profiles in saliva and blood serum. Periodontitis is a chronic inflammatory disease that affects the tissues supporting the teeth, while smoking is an important risk factor for periodontal disease.
The study will include 56 adults divided into four groups according to their periodontal health and smoking status: non-smokers with periodontitis, smokers with periodontitis, periodontally healthy non-smokers, and periodontally healthy smokers.
Saliva and blood samples will be collected from each participant. Lipid profiles will be analyzed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS). The study will examine the individual and combined associations of periodontitis and smoking with lipid profiles and explore the relationship between lipid patterns in saliva and serum.
The findings may help identify lipid-related changes associated with periodontal disease and smoking and improve our understanding of their effects on oral and systemic health.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues. Smoking is a major modifiable risk factor that influences periodontal inflammation, host immune responses, and disease progression. Both periodontitis and smoking may alter lipid metabolism and contribute to oxidative stress and inflammatory processes.
Lipidomics provides a comprehensive approach to investigating lipid species and metabolic alterations associated with disease. Saliva is a non-invasive biological fluid that may reflect both local oral conditions and systemic biological processes. Comparing salivary and serum lipidomic profiles may provide further insight into the metabolic changes associated with periodontal disease and smoking.
This observational, cross-sectional study will enroll 56 adults aged 18-65 years. Participants will be categorized into four groups based on periodontal status and smoking habits: periodontitis with smoking, periodontitis without smoking, periodontal health with smoking, and periodontal health without smoking.
Periodontal status will be determined through clinical periodontal examination. Saliva and blood samples will be obtained from the same participants, and untargeted lipidomic profiling will be performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS).
The study will assess the associations of periodontal status and smoking with salivary and serum lipidomic profiles, including their potential interaction. Relationships between lipidomic patterns in the two biological fluids will also be investigated.
This study is expected to contribute to a better understanding of lipid-related biological alterations associated with periodontitis and smoking and may support future research into potential biomarkers of periodontal disease.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nihan Akdoğan, DDS, PhD
- Phone Number: +905304070848
- Email: nihanakdogan@yahoo.com.tr
Study Contact Backup
- Name: Oğuzhan Durmaz, PhD
- Phone Number: +905369551469
- Email: durmazogz@gmail.com
Study Locations
-
-
Ankara
-
Ankara, Ankara, Turkey (Türkiye), 06560
- Recruiting
- Ankara University Faculty of Dentistry
-
Contact:
- Nihan Akdoğan, DDS, PhD
- Phone Number: +905304070848
- Email: nihanakdogan@yahoo.com.tr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will consist of 56 adults aged 18-65 years, categorized into four groups according to periodontal status and cigarette smoking: (1) patients with periodontitis who smoke, (2) patients with periodontitis who do not smoke, (3) periodontally healthy individuals who smoke, and (4) periodontally healthy individuals who do not smoke. Participants will be evaluated through clinical periodontal examinations, and saliva and serum samples will be collected for lipidomic profiling. All participants must meet the predefined eligibility criteria.
Description
Inclusion Criteria:
Individuals aged 18 years or older. Individuals who do not use orthodontic appliances Women who are not pregnant or breastfeeding. Individuals without systemic diseases that may affect periodontal health. Individuals who have not used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have not received periodontal treatment within the past year.
Exclusion Criteria:
Individuals younger than 18 years. Individuals older than 65 years. Pregnant or breastfeeding women. Individuals who have used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have received periodontal treatment within the past year. Individuals with psychiatric disorders. Individuals with any oral infection. Individuals with alcohol dependence. Individuals with active infectious diseases (acute hepatitis, AIDS, or tuberculosis), cancer, or any systemic disease that may affect periodontal tissues.
Individuals receiving medications known to affect periodontal tissues, including phenytoin, cyclosporine A, or calcium channel blockers.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: CROSS_SECTIONAL
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Periodontitis Smokers
Adult participants diagnosed with periodontitis who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontitis Non-Smokers
Adult participants diagnosed with periodontitis who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Smokers
Adult participants with clinically healthy periodontal tissues who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Non-Smokers
Adult participants with clinically healthy periodontal tissues who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Salivary Lipidomic Profile
Time Frame: At baseline (single sample collection)
|
Salivary lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
|
Serum Lipidomic Profile
Time Frame: At baseline (single sample collection)
|
Serum lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Probing Pocket Depth (PPD)
Time Frame: At baseline (single clinical examination)
|
Probing pocket depth (PPD) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean PPD values will be calculated to characterize periodontal status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Attachment Loss (AL)
Time Frame: At baseline (single clinical examination)
|
Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean AL values will be calculated to characterize periodontal tissue destruction, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Bleeding on Probing (BOP)
Time Frame: At baseline (single clinical examination)
|
Bleeding on probing (BOP) will be assessed at six sites per tooth. The percentage of sites exhibiting bleeding will be calculated to characterize gingival inflammation, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Plaque Index (PI)
Time Frame: At baseline (single clinical examination)
|
Plaque index (PI) will be assessed to quantify dental plaque accumulation. Individual plaque index scores will be calculated according to the study protocol to characterize oral hygiene status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Periodontal Diseases
- Mouth Diseases
- Stomatognathic Diseases
- Behavior
- Tobacco Smoking
- Tobacco Use
- Periodontitis
- Smoking
- Cigarette Smoking
- Health Care Quality, Access, and Evaluation
- Amino Acids, Peptides, and Proteins
- Proteins
- Investigative Techniques
- Epidemiologic Methods
- Therapeutics
- Biological Factors
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Behavior Control
- Immobilization
- Bacterial Proteins
- Health Surveys
- Surveys and Questionnaires
- Dentistry
- Antigens
- Dental Health Surveys
- Public Health Dentistry
- Antigens, Bacterial
- Weights and Measures
- Restraint, Physical
- Tuberculin
- Dental Plaque Index
- short-wavelength opsin
Other Study ID Numbers
Other Study ID Numbers
- 27/2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data (IPD) will not be shared with other researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form through scientific publications without disclosing identifiable participant information.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.